Up | AC
Home Page
Food and
Drug Administration
Antiviral Drugs Advisory Committee
April 24, 2007
Briefing Information
Pfizer, Inc.
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
MARAVIROC Tablets NDA 22-128 (pdf)
FDA
Disclaimer
Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §552).
These redacted portions will appear as white space on the screen or on the printed page.
FDA Cover Memorandum (pdf)
FDA Addendum to Collaborative Meeting Draft Report (pdf)
FDA/FCHR Collaborative Meeting Draft Report (pdf)
FDA ERRATA (pdf)